Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

NRG1 Fusions in KRAS Wild-type Pancreatic Cancer.

Heining C, Horak P, Uhrig S, Codo PL, Klink B, Hutter B, Fröhlich M, Bonekamp D, Richter D, Steiger K, Penzel R, Endris V, Ehrenberg KR, Frank S, Kleinheinz K, Toprak UH, Schlesner M, Mandal R, Schulz L, Lambertz H, Fetscher S, Bitzer M, Malek NP, Horger MS, Giese NA, Strobel O, Hackert T, Springfeld C, Feuerbach L, Bergmann F, Schröck E, von Kalle C, Weichert W, Scholl C, Ball CR, Stenzinger A, Brors B, Fröhling S, Glimm H.

Cancer Discov. 2018 May 25. pii: CD-18-0036. doi: 10.1158/2159-8290.CD-18-0036. [Epub ahead of print]

PMID:
29802158
2.

From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards.

Perera-Bel J, Hutter B, Heining C, Bleckmann A, Fröhlich M, Fröhling S, Glimm H, Brors B, Beißbarth T.

Genome Med. 2018 Mar 15;10(1):18. doi: 10.1186/s13073-018-0529-2.

3.

A Comparison of Cochlear Nerve Size in Normal-Hearing Adults Using Magnetic Resonance Imaging.

Heining C, Tikka T, Colley S, Zilinskiene L, Coulson C.

J Int Adv Otol. 2017 Dec;13(3):300-303. doi: 10.5152/iao.2017.4170. Epub 2017 Dec 14.

4.

[Personalized oncology].

Heining C, Horak P, Gröschel S, Glimm H, Fröhling S.

Radiologe. 2017 Oct;57(10):804-811. doi: 10.1007/s00117-017-0297-9. Review. German.

PMID:
28875369
5.

Audiological outcome of stapes surgery for far advanced cochlear otosclerosis.

Heining C, Banga R, Irving R, Coulson C, Monksfield P.

J Laryngol Otol. 2017 Nov;131(11):961-964. doi: 10.1017/S0022215117001815. Epub 2017 Sep 6.

PMID:
28874211
6.

Precision oncology based on omics data: The NCT Heidelberg experience.

Horak P, Klink B, Heining C, Gröschel S, Hutter B, Fröhlich M, Uhrig S, Hübschmann D, Schlesner M, Eils R, Richter D, Pfütze K, Geörg C, Meißburger B, Wolf S, Schulz A, Penzel R, Herpel E, Kirchner M, Lier A, Endris V, Singer S, Schirmacher P, Weichert W, Stenzinger A, Schlenk RF, Schröck E, Brors B, von Kalle C, Glimm H, Fröhling S.

Int J Cancer. 2017 Sep 1;141(5):877-886. doi: 10.1002/ijc.30828. Epub 2017 Jun 21.

PMID:
28597939
7.

Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification.

Gröschel S, Bommer M, Hutter B, Budczies J, Bonekamp D, Heining C, Horak P, Fröhlich M, Uhrig S, Hübschmann D, Geörg C, Richter D, Pfarr N, Pfütze K, Wolf S, Schirmacher P, Jäger D, von Kalle C, Brors B, Glimm H, Weichert W, Stenzinger A, Fröhling S.

Cold Spring Harb Mol Case Stud. 2016 Nov;2(6):a001180.

8.

Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma.

Dieter SM, Heining C, Agaimy A, Huebschmann D, Bonekamp D, Hutter B, Ehrenberg KR, Fröhlich M, Schlesner M, Scholl C, Schlemmer HP, Wolf S, Mavratzas A, Jung CS, Gröschel S, von Kalle C, Eils R, Brors B, Penzel R, Kriegsmann M, Reuss DE, Schirmacher P, Stenzinger A, Federspil PA, Weichert W, Glimm H, Fröhling S.

Ann Oncol. 2017 Jan 1;28(1):142-148. doi: 10.1093/annonc/mdw446.

PMID:
27687311
9.

Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.

Chudasama P, Renner M, Straub M, Mughal SS, Hutter B, Kosaloglu Z, Schweßinger R, Scheffler M, Alldinger I, Schimmack S, Persigehl T, Kobe C, Jäger D, von Kalle C, Schirmacher P, Beckhaus MK, Wolf S, Heining C, Gröschel S, Wolf J, Brors B, Weichert W, Glimm H, Scholl C, Mechtersheimer G, Specht K, Fröhling S.

Clin Cancer Res. 2017 Feb 15;23(4):962-973. doi: 10.1158/1078-0432.CCR-16-0860. Epub 2016 Aug 17.

10.

[Durable remission under dual HER2 blockade with Trastuzumab and Pertuzumab in a patient with metastatic gallbladder cancer].

Czink E, Heining C, Weber TF, Lasitschka F, Schemmer P, Schirmacher P, Weiss KH, Glimm H, Brors B, Weichert W, Jäger D, Fröhling S, Springfeld C.

Z Gastroenterol. 2016 May;54(5):426-30. doi: 10.1055/s-0042-103498. Epub 2016 May 12. German.

PMID:
27171333
11.

Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling.

Kordes M, Röring M, Heining C, Braun S, Hutter B, Richter D, Geörg C, Scholl C, Gröschel S, Roth W, Rosenwald A, Geissinger E, von Kalle C, Jäger D, Brors B, Weichert W, Grüllich C, Glimm H, Brummer T, Fröhling S.

Leukemia. 2016 Apr;30(4):937-46. doi: 10.1038/leu.2015.319. Epub 2015 Nov 19.

PMID:
26582644
12.

Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function.

Breitkreutz I, Becker N, Benner A, Kosely F, Heining C, Hillengass J, Egerer G, Ho AD, Goldschmidt H, Raab MS.

Hematol Oncol. 2016 Dec;34(4):200-207. doi: 10.1002/hon.2199. Epub 2015 Mar 18.

PMID:
25784529
13.

Targeting the BRAF V600E mutation in multiple myeloma.

Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J, Zenz T, von Deimling A, Schirmacher P, Ho AD, Goldschmidt H, Neben K, Raab MS.

Cancer Discov. 2013 Aug;3(8):862-9. doi: 10.1158/2159-8290.CD-13-0014. Epub 2013 Apr 23.

14.

Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].

Hoffmann K, Glimm H, Radeleff B, Richter G, Heining C, Schenkel I, Zahlten-Hinguranage A, Schirrmacher P, Schmidt J, Büchler MW, Jaeger D, von Kalle C, Schemmer P.

BMC Cancer. 2008 Nov 26;8:349. doi: 10.1186/1471-2407-8-349.

15.

Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients.

Heining C, Spyridonidis A, Bernhardt E, Schulte-Mönting J, Behringer D, Grüllich C, Jakob A, Bertz H, Finke J.

Bone Marrow Transplant. 2007 May;39(10):613-22. Epub 2007 Mar 26.

PMID:
17384658

Supplemental Content

Loading ...
Support Center